MRNA vs BNTX Stock Comparison: AI Score, Valuation, Performance and Upside
Moderna and BioNTech are the two mRNA pioneer companies that commercialized COVID-19 vaccines and are now racing to diversify their mRNA platforms beyond COVID. Both face the same fundamental challenge: COVID vaccine revenue has declined significantly from pandemic peaks, and both companies depend on next-generation vaccine approvals and oncology programs to sustain long-term revenue. BioNTech is explicitly cancer-focused; Moderna is pursuing both next-gen respiratory vaccines and oncology.
MRNA vs BNTX is a comparison between two mRNA platform companies using COVID vaccine revenue to fund the next generation of mRNA therapeutics — Moderna is diversifying into respiratory vaccines and oncology, while BioNTech is primarily focused on cancer vaccines and cell therapy. Both are long-duration clinical pipeline bets with similar near-term COVID revenue normalization risks.
BNTX holds the edge across 3 of 5 key metrics in this comparison. MRNA has delivered stronger 1-year price return (+505.27% vs -0.26%), though BNTX has the better forward P/E setup (-19.55x vs -30.13x for MRNA). MRNA leads on both revenue growth (2.10%) and operating margin (-557.93%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for BNTX (+23.10%) than for MRNA (-22.73%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- prefer the US-listed mRNA platform with a broad respiratory vaccine pipeline including RSV, flu, and COVID combination products
- value the Merck personalized cancer vaccine partnership (mRNA-4157) as a near-term oncology catalyst with Merck's commercial capabilities
- want exposure to mRNA platform expansion beyond vaccines into rare disease and latent infection therapeutic areas
- are comfortable with high cash burn and COVID revenue normalization as the pipeline advances toward commercialization
- prefer an oncology-focused mRNA company using COVID royalties to fund a pure cancer vaccine and cell therapy pipeline
- value BioNTech's multiple oncology modalities (mRNA vaccines, in vivo CAR-T, antibody-drug conjugates) as a diversified cancer approach
- want a European biotech with deep oncology R&D roots and Pfizer's global distribution ensuring Comirnaty commercial reach
- are comfortable with longer timelines to oncology revenue and COVID royalty decline as Comirnaty demand normalizes
| Metric | MRNA | BNTX |
|---|---|---|
| AI scorei | 56.5 | 58.7 |
| AI ranki | #246 | #199 |
| Latest closei | $154.04 | $96.06 |
| 1M returni | -11.66% | -15.08% |
| 6M returni | +194.14% | +7.61% |
| 1Y returni | +505.27% | -0.26% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | MRNA | BNTX |
|---|---|---|
| 1Y ago | $60.53K (+505.3%) started 2025-09-18 | $9.97K (-0.3%) started 2025-09-18 |
| 5Y ago | $3.64K (-63.6%) started 2021-09-20 | $2.91K (-70.9%) started 2021-09-20 |
| 10Y ago | $82.82K (+728.2%) started 2018-12-07 | $69.26K (+592.6%) started 2019-10-10 |
Hypothetical — past performance does not guarantee future results.
| Metric | MRNA | BNTX |
|---|---|---|
| Market capi | $55.09B | $24.13B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | -30.13 | -19.55 |
| Price/Salesi | N/A | 9.11 |
| EV/Revenuei | 23.00 | 4.14 |
| Analyst targeti | $106.63 | $118.25 |
| Target upsidei | -22.73% | +23.10% |
| Metric | MRNA | BNTX |
|---|---|---|
| Revenue growthi | 2.10% | -59.50% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | +13.43% | -9.42% |
| Operating margini | -557.93% | -806.63% |
| Profit margini | -141.43% | -63.64% |
| ROIC proxyi | -39.00% | -9.30% |
| Return on equityi | -39.00% | -9.30% |
| Dividend yieldi | N/A | 0.00% |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 0.90 | 1.29 |
| Debt/equityi | 19.04 | 1.78 |
| Current ratioi | 2.29 | 7.85 |
| Quick ratioi | 2.07 | 7.03 |
Over the past year, MRNA and BNTX have moved moderately in the same direction (correlation of 0.61), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | MRNA | BNTX |
|---|---|---|---|
| 1Y | Growthi | +505.27% | -0.26% |
| CAGRi | +506.01% | -0.26% | |
| Volatilityi | 192.18% | 45.80% | |
| Sharpe ratioi | 1.46 | 0.12 | |
| Sortino ratioi | 5.95 | 0.18 | |
| Max drawdowni | 34.16% | 29.71% | |
| Current drawdowni | 11.66% | 19.51% | |
| Avg drawdowni | 11.56% | 14.49% | |
| Ulcer Indexi | 14.35% | 16.88% | |
| Max daily dropi | 23.55% | 17.88% | |
| Max wkly dropi | 18.08% | 16.74% | |
| 5Y | Growthi | -63.61% | -71.29% |
| CAGRi | -18.32% | -22.11% | |
| Volatilityi | 103.99% | 52.96% | |
| Sharpe ratioi | 0.12 | -0.29 | |
| Sortino ratioi | 0.28 | -0.42 | |
| Max drawdowni | 95.08% | 78.10% | |
| Current drawdowni | 66.12% | 73.15% | |
| Avg drawdowni | 76.44% | 65.03% | |
| Ulcer Indexi | 78.10% | 66.33% | |
| Max daily dropi | 23.55% | 20.92% | |
| Max wkly dropi | 33.81% | 29.13% | |
| 10Y | Growthi | +728.17% | +583.51% |
| CAGRi | +31.21% | +31.91% | |
| Volatilityi | 96.54% | 75.42% | |
| Sharpe ratioi | 0.61 | 0.67 | |
| Sortino ratioi | 1.24 | 1.10 | |
| Max drawdowni | 95.38% | 82.25% | |
| Current drawdowni | 68.20% | 78.24% | |
| Avg drawdowni | 57.58% | 57.17% | |
| Ulcer Indexi | 65.45% | 62.88% | |
| Max daily dropi | 23.55% | 35.54% | |
| Max wkly dropi | 33.81% | 48.70% |
| Category | MRNA | BNTX |
|---|---|---|
| Company | Moderna, Inc. | BioNTech SE |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | Moderna is a pure-play mRNA therapeutics company that commercialized the first mRNA COVID-19 vaccine and is advancing mRNA programs across respiratory vaccines (RSV, flu, COVID combo), oncology (personalized cancer vaccines with Merck), rare disease (PA, MMA), and latent infection (CMV). Its drug design and manufacturing platform allows rapid vaccine development for novel pathogens. Moderna's entire revenue base currently depends heavily on COVID vaccine sales, which have declined sharply from pandemic peaks. | BioNTech developed the mRNA COVID vaccine (Comirnaty) in partnership with Pfizer and uses royalties and partnership revenue to fund a broad oncology pipeline — cancer vaccines, in vivo CAR-T therapies, checkpoint immunomodulators, and antibody-drug conjugates. Unlike Moderna, BioNTech's long-term strategy is explicitly cancer-focused, with COVID vaccine revenue used as a funding vehicle. BioNTech's oncology pipeline spans individualized neoantigen-specific immunotherapy (iNeST), mRNA cancer vaccines, and cell therapy approaches. |
| Investor focus | Investors track non-COVID mRNA vaccine revenue milestones (RSV, flu combination), personalized cancer vaccine partnership progress with Merck (mRNA-4157/V940), cash runway as Moderna invests heavily in a broad R&D pipeline, and any new infectious disease preparedness contracts. | Investors focus on oncology clinical trial readouts (mRNA cancer vaccine pivotal trials, CAR-T programs), Comirnaty COVID royalty revenue trajectory, BNT111/BNT113 cancer vaccine phase 2/3 data, and cash management as the company invests royalties into oncology R&D. |
- End-to-end mRNA platform capable of designing, manufacturing, and delivering novel mRNA vaccines faster than traditional vaccine platforms
- Personalized cancer vaccine partnership with Merck (mRNA-4157) showed landmark efficacy data in melanoma, opening a new category
- Significant cash reserves from COVID vaccine revenue provide multi-year runway to commercialize next-generation respiratory vaccines
- Oncology-focused pipeline using COVID revenue as a funding vehicle for multiple cancer vaccine and cell therapy approaches
- Partnership with Pfizer for commercial distribution enables Comirnaty global reach without BioNTech building its own commercial infrastructure
- iNeST personalized cancer vaccine program competes directly with Moderna/Merck in the same high-value category
- COVID vaccine revenue declining sharply as endemic-level demand settles far below pandemic peak — creates severe revenue cliff
- RSV and combination flu/COVID vaccines face competition from Pfizer and established RSV vaccines from GSK and AstraZeneca
- Burn rate is high as Moderna invests in 40+ pipeline programs while COVID revenue normalizes
- COVID vaccine royalties declining as endemic-level COVID demand normalizes — same revenue cliff issue as Moderna
- Cancer vaccine clinical programs are years from commercialization — requires sustained investment from existing cash reserves
- Pfizer controls commercial execution of Comirnaty, limiting BioNTech's direct pricing and distribution control
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.